The position of a **postdoctoral researcher (m/f)**

is available in Cardiovascular group of the Pole of Pharmacology and Therapeutics, Institute for Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL), Brussels.

Starting date: March 2018

Duration: initially 2 years; option for further extension

UCL is one of the leading research universities in Belgium and Europe (ranked among the top 150 universities worldwide) with more than 3000 researchers (a third being international), 21 research institutes and 2 major university hospitals (www.uclouvain.be). The position is open on the UCL campus in Brussels.

The candidate will work on new mechanisms of **signalling by free radicals (e.g. nitric oxide and reactive oxygen species)** through specific membrane proteins, in the context of endothelial dysfunction and myocardial remodelling. He/she will also be involved in genotype/phenotype correlations with regard to polymorphisms for specific genes coding these membrane proteins in human cohorts and in validation studies in transgenic animals. For more details or discussion of the project, contact: jl.balligand@uclouvain.be

Applicants must hold a PhD in Biology/Biochemistry (or an equivalent scientific degree), be highly motivated, independent and senior enough to organise the work of technicians and doctoral students and integrate themselves into a team. An excellent background in molecular biology and experimental animal work is required, as is fluently spoken English. A background in bioinformatics is an advantage.

The candidate will work in an international and highly motivated, well-financed environment with state-of-the art equipment in the technological platforms of IREC. He/she will benefit from networking within the Welbio consortium which subsidises the project (www.welbio.org).

Applications including a full CV, publication list (at least two publications as first author in international journals with impact factor ≥ 5 are mandatory), as well as the contact addresses of 2 referees should be sent to:
Ms. M-P Landenne (P.A. to Prof J-L Balligand) Pole of Pharmacology and Therapeutics, FATH 5349, Tour Vesale +5, 52 ave Mounier, 1200 Brussels (marie-pierre.landenne@uclouvain.be)

The position is available as early as March 2018.